Novelties in Primary and Metastatic GEP-NENs Clinical Outcome Investigation


Introduction: Gastro-entero-pancreatic neuroendocrine neoplasms (GEP-NENs) WHO classification, using strict cut-offs, should reflect their biological features. In real world, strict cut-offs not adequately segregate prognostic groups, in particular on metastasis (M).

Aim(s): To investigate GEP-NENs clinical outcome in primary tumors (T) and M.

Materials and methods: 264 patients from 3 Italian centers were analyzed regarding: morphology, mitoses and Ki67 considering both in T, lymph node (N) and M. Ki67 and mitoses were studied both as WHO cut-offs (namely Ki67 LI – MI) and in continuous scale (namely Ki67 - Mitoses). Clinical endpoints were overall survival (OS) and relapse-free survival (RFS). With same aim T stage, N, and tumor deposits (TD) were considered.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Milione M

Authors: Kankava K, Maisonneuve P, Mangogna A, Centonze G, Cattaneo L,

Keywords: Gastro-entero-pancreatic neuroendocrine neoplasms, primary tumor, metastasis, Ki-67, mitoses, tumor deposits, clinical outcomes,

To read the full abstract, please log into your ENETS Member account.